FDA lists 205 molecular targets for pediatric cancer research
To help with anti-cancer drug development, the FDA has developed two new lists of molecular targets to guide submissions for pediatric study plans.
The two lists, posted Tuesday by the FDA’s Oncology Center of Excellence, are aimed at fostering the development of new oncology drugs or biologics for pediatric populations. They also fulfill a commitment the agency made under the FDA Reauthorization Act of 2017 (FDARA).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.